{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T23:09:10Z","timestamp":1773356950793,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.clinthera.2014.06.022","type":"journal-article","created":{"date-parts":[[2014,7,10]],"date-time":"2014-07-10T20:04:41Z","timestamp":1405022681000},"page":"1159-1170","source":"Crossref","is-referenced-by-count":11,"title":["Pharmacokinetic Interaction Between Rosuvastatin and Olmesartan: A Randomized, Open-label, 3-period, Multiple-dose Crossover Study in Healthy Korean Male Subjects"],"prefix":"10.1016","volume":"36","author":[{"given":"Hyerang","family":"Roh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hankil","family":"Son","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HeeChul","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chohee","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyungsoo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11 Pt 2","key":"10.1016\/j.clinthera.2014.06.022_bib1","doi-asserted-by":"crossref","first-page":"303S","DOI":"10.1093\/ajh\/6.11.303S","article-title":"Hypertension and hyperlipidemia. A review","volume":"6","author":"Lithell","year":"1993","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.clinthera.2014.06.022_bib2","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1177\/009127002401102876","article-title":"A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin","volume":"42","author":"White","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2014.06.022_bib3","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2014.06.022_bib4","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.clinthera.2007.07.019","article-title":"A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia","volume":"29","author":"Kostapanos","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2014.06.022_bib5","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.clinthera.2004.09.006","article-title":"Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial","volume":"26","author":"Jones","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2014.06.022_bib6","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.clinthera.2010.03.018","article-title":"Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study","volume":"32","author":"Rizos","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2014.06.022_bib7","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1742-1241.2009.02101.x","article-title":"Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidemic patients with impaired fasting glucose","volume":"63","author":"Kostapanos","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.clinthera.2014.06.022_bib8","unstructured":"Crestor Tablets. Accessdata FDA. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/21366slr005lbl.pdf. Accessed June 20, 2013."},{"key":"10.1016\/j.clinthera.2014.06.022_bib9","first-page":"282","article-title":"Olmesartan medoxomil: a clinical review","volume":"58","author":"Manoria","year":"2006","journal-title":"Indian Heart J"},{"key":"10.1016\/j.clinthera.2014.06.022_bib10","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.2165\/00003495-200868090-00005","article-title":"Olmesartan medoxomil: a review of its use in the management of hypertension","volume":"68","author":"Scott","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2014.06.022_bib11","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/01.fjc.0000180902.78230.fd","article-title":"A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker","volume":"46","author":"Mire","year":"2005","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.clinthera.2014.06.022_bib12","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.bmcl.2012.12.090","article-title":"Discovery of olmesartan hexetil: a new potential prodrug of olmesartan","volume":"23","author":"El-Gamal","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.clinthera.2014.06.022_bib13","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1124\/dmd.113.053595","article-title":"Different hydrolases involved in bioactivation of prodrug-type angiotensin receptor blockers: carboxymethylenebutenolidase and carboxylesterase 1","volume":"41","author":"Ishizuka","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2014.06.022_bib14","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1124\/dmd.111.041475","article-title":"Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism","volume":"40","author":"Ishizuka","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2014.06.022_bib15","unstructured":"Benicar (olmesartan medoxomil) tablet label. Accessdata FDA. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021286s023lbl.pdf. Accessed June 20, 2013."},{"key":"10.1016\/j.clinthera.2014.06.022_bib16","unstructured":"Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects, 2008. http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/. Accessed February 25, 2013."},{"key":"10.1016\/j.clinthera.2014.06.022_bib17","unstructured":"Ministry of Food and Drug Safety (MFDS). Korea Good Clinical Practice (KGCP) guidelines [in Korean]. http:\/\/drugsafe.or.kr\/iwt\/ds\/ko\/bbs\/EgovBbs.do?bbsId=BBSMSTR_000000000041&nttId=267. Accessed December 8, 2013."},{"key":"10.1016\/j.clinthera.2014.06.022_bib18","unstructured":"Ministry of Food and Drug Safety (MFDS)\/ Guidance for drug interaction studies and labeling. Ver-1.4, 2011 [in Korean]. http:\/\/www.mfds.go.kr\/index.do?mid=1161&searchkey=title%3Acontents&searchword=%BB%F3%C8%A3%C0%DB%BF%EB&x=31&y=13. Accessed December 8, 2013."},{"key":"10.1016\/j.clinthera.2014.06.022_bib19","series-title":"Design and Analysis of Bioavailability and Bioequivalence Studies","first-page":"307","author":"Chow","year":"2008"},{"key":"10.1016\/j.clinthera.2014.06.022_bib20","unstructured":"National Institute of Toxicological Research (NITR). Guideline on Food-Effect Bioavailability and Fed Bioequivalence Studies [in Korean]. http:\/\/www.mfds.go.kr\/index.do?mid=695&seq=714&cmd=v. Accessed December 8, 2013."},{"key":"10.1016\/j.clinthera.2014.06.022_bib21","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clinthera.2010.03.015","article-title":"Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study","volume":"32","author":"Li","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2014.06.022_bib22","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1472-8206.2009.00720.x","article-title":"Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects","volume":"23","year":"2009","journal-title":"Fund Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2014.06.022_bib23","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jpba.2003.12.022","article-title":"Quantification of the N-desmethyl metabolite of rosuvastatin in human plasma by automated SPE followed by HPLC with tandem MS detection","volume":"35","author":"Hull","year":"2004","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.clinthera.2014.06.022_bib24","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1570-0232(02)00088-0","article-title":"Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detection","volume":"772","author":"Hull","year":"2002","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.clinthera.2014.06.022_bib25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jchromb.2007.05.049","article-title":"Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry","volume":"856","author":"Liu","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.clinthera.2014.06.022_bib26","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research, Guidance for Industry: Drug Interaction Studies\u2014Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations, 2012. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm292362.pdf. Accessed April 27, 2014."},{"key":"10.1016\/j.clinthera.2014.06.022_bib27","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.clinthera.2013.05.016","article-title":"Pharmacokinetics of rosuvastatin\/olmesartan fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects","volume":"35","author":"Son","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2014.06.022_bib28","unstructured":"Ministry of Food and Drug Safety (MFDS). Guidance for Bioequivalence Studies [in Korean]. http:\/\/www.mfds.go.kr\/index.do?mid=1161&searchkey=title%3Acontents&searchword=%BB%FD%B9%B0%C7%D0%C0%FB%B5%BF%B5%EE%BC%BA%BD%C3%C7%E8%B1%E2%C1%D8&x=17&y=7. Accessed April 27, 2014."},{"key":"10.1016\/j.clinthera.2014.06.022_bib29","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1124\/dmd.108.021410","article-title":"Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin","volume":"36","author":"Kitamura","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2014.06.022_bib30","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1124\/dmd.107.017459","article-title":"Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor","volume":"35","author":"Yamada","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2014.06.022_bib31","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/bdd.699","article-title":"Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters","volume":"31","author":"Weiss","year":"2010","journal-title":"Biopharm Drug Dispos"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814003865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814003865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T18:27:25Z","timestamp":1538418445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291814003865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0149291814003865"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.06.022","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]}}}